Sirtuins are NAD 1 -dependent protein deacetylases. They mediate adaptive responses to a variety of stresses, including calorie restriction and metabolic stress. Sirtuin 3 (SIRT3) is localized in the mitochondrial matrix, where it regulates the acetylation levels of metabolic enzymes, including acetyl coenzyme A synthetase 2 (refs 1, 2). Mice lacking both Sirt3 alleles appear phenotypically normal under basal conditions, but show marked hyperacetylation of several mitochondrial proteins 3 . Here we report that SIRT3 expression is upregulated during fasting in liver and brown adipose tissues. During fasting, livers from mice lacking SIRT3 had higher levels of fatty-acid oxidation intermediate products and triglycerides, associated with decreased levels of fatty-acid oxidation, compared to livers from wild-type mice. Mass spectrometry of mitochondrial proteins shows that long-chain acyl coenzyme A dehydrogenase (LCAD) is hyperacetylated at lysine 42 in the absence of SIRT3. LCAD is deacetylated in wild-type mice under fasted conditions and by SIRT3 in vitro and in vivo; and hyperacetylation of LCAD reduces its enzymatic activity. Mice lacking SIRT3 exhibit hallmarks of fatty-acid oxidation disorders during fasting, including reduced ATP levels and intolerance to cold exposure. These findings identify acetylation as a novel regulatory mechanism for mitochondrial fatty-acid oxidation and demonstrate that SIRT3 modulates mitochondrial intermediary metabolism and fatty-acid use during fasting.
Sirtuins are NAD 1 -dependent protein deacetylases. They mediate adaptive responses to a variety of stresses, including calorie restriction and metabolic stress. Sirtuin 3 (SIRT3) is localized in the mitochondrial matrix, where it regulates the acetylation levels of metabolic enzymes, including acetyl coenzyme A synthetase 2 (refs 1, 2) . Mice lacking both Sirt3 alleles appear phenotypically normal under basal conditions, but show marked hyperacetylation of several mitochondrial proteins 3 . Here we report that SIRT3 expression is upregulated during fasting in liver and brown adipose tissues. During fasting, livers from mice lacking SIRT3 had higher levels of fatty-acid oxidation intermediate products and triglycerides, associated with decreased levels of fatty-acid oxidation, compared to livers from wild-type mice. Mass spectrometry of mitochondrial proteins shows that long-chain acyl coenzyme A dehydrogenase (LCAD) is hyperacetylated at lysine 42 in the absence of SIRT3. LCAD is deacetylated in wild-type mice under fasted conditions and by SIRT3 in vitro and in vivo; and hyperacetylation of LCAD reduces its enzymatic activity. Mice lacking SIRT3 exhibit hallmarks of fatty-acid oxidation disorders during fasting, including reduced ATP levels and intolerance to cold exposure. These findings identify acetylation as a novel regulatory mechanism for mitochondrial fatty-acid oxidation and demonstrate that SIRT3 modulates mitochondrial intermediary metabolism and fatty-acid use during fasting.
Proteomic analysis of mitochondrial proteins revealed the acetylation levels of numerous mitochondrial proteins change during fasting 4 . The dependence of SIRT3 enzymatic activity on NAD 1 suggests that SIRT3 serves as a metabolic sensor and couples the energy status of the cell with the level of mitochondrial protein acetylation [5] [6] [7] . To explore further a possible role of SIRT3 in regulating metabolism, we monitored the protein expression level of hepatic SIRT3 during fasting in wild-type mice. Although hepatic SIRT3 expression was low under basal conditions, its expression was induced during fasting (Fig. 1a ). The increase in SIRT3 protein expression during fasting was concomitant with a relative decrease in the acetylation levels of some mitochondrial proteins (two indicated by arrows in Fig. 1b ), suggesting that SIRT3 mediated their deacetylation.
In agreement with this model, the same two proteins were hyperacetylated in Sirt3 2/2 mice under basal conditions, and their acetylation levels did not change with fasting when SIRT3 was missing ( Fig. 1b) . Interestingly, the level of acetylation of other mitochondrial proteins did not change during fasting or in the absence of SIRT3, demonstrating the selectivity of SIRT3-mediated deacetylation ( Fig. 1b ). SIRT3 expression was also upregulated in response to fasting in brown adipose tissue but not in the brain, heart or kidney (Supplementary Fig. 2 ).
Because the liver is an important site of metabolic regulation under fasting conditions, we used a metabolomic approach to screen multiple metabolic pathways. No differences were observed in the levels of 15 amino acids and eight organic acids in livers between fasted 1 Gladstone Institute of Virology and Immunology, San Francisco, California 94158, USA. 2 
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Anti-ATP synthase-α a, Mitochondria were isolated from livers of fed or fasted (6-48 h) wild-type mice and analysed for SIRT3 expression by western blot analysis; ETF was used as a reference. b, Mitochondria isolated from livers of fed or fasted wildtype (WT) and Sirt3 2/2 mice were analysed by western blotting with an antiserum specific for anti-acetyllysine; ATP synthase-a was used as a reference. The arrows identify candidate SIRT3 target proteins that were deacetylated during fasting in wild-type mice, and relatively hyperacetylated and not deacetylated during fasting in Sirt3 2/2 mice.
wild-type and Sirt3 2/2 mice ( Supplementary Figs 3 and 4 , respectively). However, several abnormalities in products of lipid metabolism were found ( Fig. 2 ). Long-chain acylcarnitine species accumulated in the liver ( Fig. 2a ), but not medium-or short-chain acylcarnitines (data not shown), suggestive of incomplete oxidation of long-chain fatty acids. Analysis of plasma acylcarnitine revealed a striking positive relation between the abundance of acylcarnitines and their chain length: long-chain acylcarnitines (longer than 16 carbon atoms) accumulated in the plasma in Sirt3 2/2 mice and short-chain acylcarnitine species (shorter than 16 carbon atoms) were found in lower amounts compared with wild-type mice ( Fig. 2b and Supplementary Fig. 5 ). We hypothesized that this trend resulted from the inability of Sirt3 2/2 mice to oxidize long-chain acyl substrates, resulting in their accumulation in plasma. In addition, we predicted reduced oxidation of long-chain acyl substrates in Sirt3 2/2 mice accounts for reduced levels of short-chain acyl substrates. Urinalysis of Sirt3 2/2 mice showed increased urine methylsuccinate, ethylmalonate and isobutyrylglycine, further supporting a defect in fatty-acid oxidation ( Supplementary Fig. 6 ).
In addition, biochemical analysis of tissue revealed increased hepatic triglycerides in Sirt3 2/2 mice (Fig. 2c ). Liver triglyceride levels were comparable under fed conditions between wild-type and Sirt3 2/2 mice. Triglyceride levels markedly increased during fasting in wild-type mice, consistent with the mobilization of fatty acids from adipose tissue to the liver. This accumulation was further exacerbated in mice lacking SIRT3 ( Fig. 2c ), suggesting abnormal fatty-acid metabolism.
Hepatic steatosis is highly correlated with reduced lipid oxidation [8] [9] [10] . To assess fatty-acid oxidation directly, ex vivo palmitate oxidation was measured in liver homogenates from wild-type and Sirt3 2/2 mice by assessing the rate of conversion of radiolabelled palmitate into either acid-soluble metabolites ( Fig. 3a ) or CO 2 (Fig. 3b ). Under low substrate concentrations, wild-type and Sirt3 2/2 tissue homogenates showed equal abilities to oxidize palmitate ( Fig. 3a, b ). However, as lipid concentrations increased, we found that liver tissue from fasted Sirt3 2/2 mice had a lower oxidizing capacity than wild-type tissue ( Fig. 3a, b ). Fatty-acid oxidation was also measured in other oxidizing tissues from fasted mice: significant reductions were observed in cardiac muscle (33% lower in Sirt3 2/2 than wild-type mice), in mixed skeletal muscle (51% lower) and in brown adipose tissue (36% lower) ( Fig. 3c ). This defect in fatty-acid oxidation appeared to be specific, because citrate synthase activity, a key enzyme of the Krebs cycle and indicator of mitochondrial function, was comparable in wild-type and Sirt3 2/2 mice ( Supplementary Fig. 7a ). Additionally, mitochondria from Sirt3 2/2 mice were morphologically similar to wild-type mitochondria, as observed by electron microscopy ( Supplementary  Fig. 7b , c). Because other abnormalities in lipid metabolism could contribute to hepatic steatosis, we directly measured lipogenesis and fattyacid uptake in primary hepatocytes from wild-type and Sirt3 2/2 mice; however, we observed no differences ( Supplementary Fig. 8a, b , respectively). Additionally, no differences were measured in hepatic very-low-density lipoprotein export between wild-type and Sirt3 2/2 mice ( Supplementary Fig. 8c ). These data support the model that mice lacking SIRT3 develop hepatic steatosis as a result of a unique defect in fatty-acid oxidation. To determine whether reduced fatty-acid oxidation in Sirt3 2/2 mice was cell autonomous, recombinant adenovirus overexpressing SIRT3, or green fluorescent protein (GFP) as a control, were injected into the tail veins of wild-type and Sirt3 2/2 mice. Homogenates of hepatic tissue were collected and assessed for palmitate oxidation. We found an approximate 50% reduction in fatty-acid oxidation between wild-type and Sirt3 2/2 mice after injection of GFP-expressing adenovirus (Fig. 3d) , consistent with our previous findings (Fig. 3a) . In contrast, we found no difference in palmitate oxidation between wild-type and Sirt3 2/2 mice after injection of SIRT3-expressing adenovirus (Fig. 3d ). Furthermore, we found only a modest increase in palmitate oxidation in wild-type mice after SIRT3-overexpression ( Fig. 3d ). These data demonstrate that the reduction in fatty-acid oxidation observed in mice lacking SIRT3 is a direct result of the absence of SIRT3 in liver, and can be mitigated by exogenous SIRT3 overexpression.
Based on reduced palmitate oxidation and because long-chain acylcarnitines accumulated in the liver and plasma of Sirt3 2/2 mice, we hypothesized that acetylation regulates the activity of key enzymes involved in long-chain fatty-acid degradation. To identify possible SIRT3 targets and to define further the mechanism by which hyperacetylation of mitochondrial proteins results in reduced fatty-acid oxidation, purified hepatic mitochondria were isolated from Sirt3 2/2 mice. They were then subjected to proteolytic digestion (trypsin), immunoprecipitated by anti-acetyllysine antiserum, and analysed by nanoflow liquid chromatography tandem mass spectrometry and ion-trap mass spectrometry. One key enzyme involved in the oxidation of long-chain substrates was identified, LCAD, which contained eight acetylation sites ( Supplementary Fig. 9 ).
Next, we assessed the acetylation level of hepatic LCAD. Endogenous mitochondrial proteins were immunoprecipitated with anti-acetyllysine antiserum and analysed by western blotting using antisera specific for LCAD. This experiment demonstrated LCAD was acetylated and became deacetylated during fasting in wild-type mice (Fig. 4a ). When the same experiment was conducted using mitochondria from Sirt3 2/2 mice, LCAD was relatively hyperacetylated in the fed state and not deacetylated during fasting, demonstrating that SIRT3 is necessary for LCAD deacetylation during fasting (Fig. 4a) .
To test the ability of SIRT3 to deacetylate LCAD directly, expression vectors encoding Flag-tagged murine LCAD were cotransfected with an expression vector for either SIRT3, SIRT3-H248Y (a catalytically inactive SIRT3 mutant), SIRT4 or SIRT5 into HEK-293 cells. Acetylation levels for murine LCAD were measured after immunoprecipitation (anti-Flag) by western blotting with anti-acetyllysine antiserum. SIRT3, but not SIRT3-H248Y, SIRT4 or SIRT5, deacetylated LCAD (Fig. 4b) . Additionally, to measure the ability of SIRT3 to deacetylate LCAD in vitro directly, recombinant LCAD purified after overexpression in Escherichia coli was incubated with recombinant SIRT3 wild-type or SIRT3-H248Y. Recombinant LCAD was probed for changes in acetylation by western blotting with anti-acetyllysine antiserum. SIRT3, but not SIRT3-H248Y, deacetylated LCAD in vitro (Fig. 4c ). We also tested whether SIRT3 could directly interact with LCAD by co-immunoprecipitation. We found both SIRT3 and SIRT3-H248Y, but not SIRT4 and SIRT5, interacted with LCAD ( Fig. 4d ). To determine whether SIRT3 could deacetylate human LCAD with a similar ability as murine LCAD, we measured deacetylation in vitro and in vivo and found it effectively did so (Supplementary Fig. 10 ). Although the role of human LCAD in fatty-acid oxidation is incompletely understood, the high sequence homology between mouse and human LCAD ( Supplementary Fig. 10) , the robust expression level of LCAD in human liver 11 , and similar tissue expression patterns between LCAD and other fatty-acid oxidation enzymes 11 suggest an important role for LCAD in fatty-acid oxidation in humans, as in mice. in vivo and in vitro, and displays increased enzymatic activity when deacetylated. a, Liver extracts from wild-type and Sirt3 2/2 mice (fed or fasted) were immunoprecipitated with an anti-acetyllysine antiserum and analysed with anti-LCAD antiserum. IB, immunoblot. b, Expression vectors for wild-type SIRT3, SIRT3-H248Y (catalytically inactive SIRT3 mutant), SIRT4 or SIRT5 were co-transfected with expression vectors for Flag-tagged LCAD, and the level of LCAD acetylation assessed. HA, haemagglutinin tagged. c, Recombinant LCAD expressed in E. coli was incubated in vitro with recombinant SIRT3 or SIRT3-H248Y, and the status of LCAD acetylation assessed. d, Expression vectors for wild-type SIRT3, SIRT3-H248Y, SIRT4 and SIRT5 (HA-tagged) were co-transfected with expression vectors for Flagtagged LCAD and assessed for interaction by co-immunoprecipitation. e, LCAD was expressed, purified, and incubated with SIRT3 or SIRT3-H248Y and its enzymatic activity measured in vitro using 2,6-dimethylheptanoyl-CoA as a substrate (n 5 4 independent assays). f, Recombinant LCAD was expressed in E. coli in the absence (control) or presence of nicotinamide (NAM, 50 mM), purified and its enzymatic activity measured in vitro using 2,6-dimethylheptanoyl-CoA as a substrate (n 5 4 independent assays). g, Expression vectors for wild-type LCAD, LCAD single acetylation-point mutant (LCAD-K42R) or LCAD eight acetylation-point mutant (LCAD-8KR) were co-transfected with expression vectors for wild-type SIRT3 or SIRT3-H248Y, and the level of acetylation assessed. h, Wild-type LCAD, LCAD-K42R or LCAD-8KR were expressed in HEK-293 cells and measured for enzymatic activity in vitro using 2,6-dimethylheptanoyl-CoA as a substrate (n 5 5 measurements per sample; error bars represent data from two independent protein purifications). *P , 0.05, **P , 0.01.
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To determine whether the acetylation state of LCAD modified its enzymatic activity, LCAD was overexpressed in HEK-293 with SIRT3 or with SIRT3-H248Y, purified by immunoprecipitation and assayed for LCAD enzymatic activity using 2,6-dimethylheptanoyl-CoA, a highly specific substrate for LCAD. Co-expression of LCAD with SIRT3 induced LCAD deacetylation (Fig. 4b) , and a twofold increase in enzymatic activity was observed (Fig. 4e ). However, when LCAD was overexpressed in the presence of SIRT3-H248Y, enzymatic activity was similar to basal levels observed with LCAD only (Fig. 4e ). We also overexpressed recombinant LCAD in E. coli with or without nicotinamide (50 mM), which induced its hyperacetylation, as reported for acetyl-CoA synthetase 2 (ref. 1) , and observed that hyperacetylated LCAD showed an approximate 40% reduction in enzymatic activity (Fig. 4f) .
To determine which of the eight identified acetylated lysine residues on LCAD were targets of SIRT3, we analysed semiquantitative mass spectrometry data. We found that LCAD lysine 42 was significantly hyperacetylated in Sirt3 2/2 compared with wild-type mice (a greater than 20-fold increase) ( Supplementary Fig. 10 ). Expression vectors for a single-site mutant LCAD (LCAD-K42R) and for an eight-site mutant LCAD (mutating lysine residues 42, 156, 189, 240, 254, 318, 322 and 358, LCAD-8KR) were generated, transfected in HEK-293 cells and assayed for acetylation and enzymatic activity. Both mutants, LCAD-8KR and LCAD-K42R, were notably less acetylated than wild-type LCAD under basal conditions and were not (LCAD-8KR) or minimally (LCAD-K42R) further deacetylated by SIRT3 (Fig. 4g) . Interestingly, the LCAD-8KR mutant showed only a small reduction in acetylation compared with LCAD-K42R (Fig. 4g ), supporting the model that lysine 42 is the major site of acetylation in LCAD.
Finally, to measure the effect of constitutive deacetylation in the single-site (LCAD-K42R) and eight-site (LCAD-8KR) LCAD mutants on their enzymatic activity, we purified both proteins by immunoprecipitation (anti-Flag) after overexpression in HEK-293 cells. We found a significant increase in enzymatic activity of the LCAD-K42R protein compared with wild-type LCAD (Fig. 4h ). However, no residual enzymatic activity was measured in the mutant LCAD-8KR (Fig. 4h ). These data identify LCAD lysine 42 as a critical lysine residue for the regulation of LCAD enzymatic activity. Because lysine 42 is also the primary site of LCAD acetylation and is regulated by SIRT3, these observations are consistent with the model that SIRT3 regulates LCAD enzymatic activity by the deacetylation of lysine 42.
Finally, we further explored the consequence of decreased fatty-acid oxidation in Sirt3 2/2 mice on hepatic ATP levels during fasting. In agreement with the defect in fatty-acid oxidation described earlier in Sirt3 2/2 mice, we found hepatic ATP levels to be significantly lower in fasted Sirt3 2/2 mice (43% reduction) than wild-type mice (Fig. 5a ). These data further support a recent observation describing reduced ATP levels in multiple highly oxidizing tissues in Sirt3 2/2 mice 12 . We measured additional metabolic parameters in Sirt3 2/2 mice under fed and fasted conditions, including glucose and free fatty acids, and found no differences compared with wild-type mice ( Supplementary  Table 1 ). However, measurements of ketone bodies under fasting conditions revealed reduced b-hydroxybutyrate (15% reduction) in Sirt3 2/2 mice, consistent with reduced fatty-acid oxidation (Supplementary Table 1 ).
Cold exposure is another metabolic stress associated with enhanced fatty-acid oxidation, and reduced cold tolerance is a common feature of fatty-acid oxidation deficiency in mice 13, 14 . Accordingly, Sirt3 2/2 mice exhibited a striking cold intolerance during fasting (Fig. 5b) . In contrast, fed Sirt3 2/2 mice showed cold tolerance comparable to wild-type mice (Fig. 5b ). Previous studies have established a link between reduced fatty-acid oxidation and glucose metabolism 15, 16 . We therefore assessed glucose levels during cold exposure. Plasma glucose levels increased similarly in fed Sirt3 2/2 and wild-type mice during cold exposure (Fig. 5c ). However, when fasted, Sirt3 2/2 mice showed almost no increase in plasma glucose in response to cold (9% increase) compared with wild-type mice (119% increase) ( Fig. 5c ). We postulate that reduced glucose in cold-challenged Sirt3 2/2 mice is caused by decreased fatty-acid oxidation, and reduced ATP available for gluconeogenesis 15, 16 . Together, these observations identify a novel metabolic regulatory mechanism for fatty-acid oxidation based on the reversible deacetylation of a key fatty-acid oxidation enzyme by the sirtuin SIRT3.
Previously, SIRT3 was proposed to have a role in metabolic regulation based on two prominent findings. First, reduced SIRT3 protein expression has been observed in metabolic disorders, such as leptin insufficiency 17 and type II diabetes 18 . Second, SIRT3 requires NAD 1 as a cofactor 19 , which couples its enzymatic activity with the metabolic state of the cell. Thus SIRT3 would be enzymatically more active when the NAD 1 /NADH ratio is high, which has been previously reported to occur in response to metabolic stress 20 . Conversely, when the NAD 1 /NADH ratio is low, SIRT3 enzymatic activity is expected to be low. The direct requirement for NAD 1 by SIRT3 could therefore serve as a sensitive, fast-acting sensor of the metabolic state, and positions SIRT3 to respond to cellular energy fluctuations by changes in its enzymatic activity. intolerance and hypoglycaemia. a, Hepatic ATP levels were measured in fed and fasted wild-type and Sirt3 2/2 mice (n 5 5 per genotype per condition). b, c, Core temperature (b) and blood glucose (c) were measured in fed and fasted wild-type and Sirt3 2/2 mice exposed to cold (4 uC) for 6 h (n 5 5 per genotype per condition). *P , 0.05, **P , 0.01.
Because the fatty-acid oxidation pathway is a major contributor to the regulation of cellular energy balance, especially during fasting 21, 22 , the upregulation of SIRT3 expression and the increase in cellular NAD 1 that both occur during the transition to fasting 20 could work in synergy to maximally induce SIRT3 deacetylation of LCAD-K42, and subsequent increases in LCAD activity and fatty-acid oxidation output.
We demonstrate that increased SIRT3 expression and activity deacetylates and enzymatically activates the fatty-acid oxidation enzyme LCAD. The abundance of acetylated mitochondrial proteins 4 suggests that other mitochondrial proteins in the fatty-acid oxidation pathway could be regulated by reversible acetylation and might be targets of SIRT3 or other mitochondrial sirtuins. Whether Sirt3 2/2 mice are sensitive to other conditions where energy demand is high, or have metabolic defects in additional oxidative tissues, remains unknown. Because inhibitors or genetic lesions in the fatty-acid oxidation pathway are associated with several metabolic disorders, including diabetes 23 , cardiovascular disease 24 and steatosis/steatohepatitis 25 , future experiments will examine the possible pathogenic role of SIRT3 in these conditions and address the potential therapeutic value of enhancing SIRT3 activity in these disorders.
METHODS SUMMARY
Antibodies used were specific for ATP synthase subunits a and b (Invitrogen Molecular Probes), monoclonal and polyclonal acetyllysine (Cell Signaling Technology), SIRT3 (as described 3 ), electron transfer flavoprotein (ETF) and LCAD (provided by J. Vockley). Oxidation of [1-14 C]palmitic acid by tissue homogenate was adapted from a previously established method 26 . Briefly, tissue was homogenized in sucrose/Tris/EDTA buffer, incubated for 30-60 min in the reaction mixture (pH 8.0) containing [1-14 C]palmitic acid, and measured for acid-soluble metabolites and trapped CO 2 . Enzymatic activity for LCAD was measured by the anaerobic ETF fluorescence reduction assay 27 , using 2,6-dimethyheptanoyl-CoA as a substrate in recombinant LCAD expressed and purified from HEK-293T cells with wild-type or catalytically inactive SIRT3, or in E. coli in the absence (control) or presence of nicotinamide (50 mM) 28 .
